

Rating: BUY | CMP: Rs1,520 | TP: Rs1,730

May 14, 2025

Q4FY25 Result Update

☑ Change in Estimates | ■ Target | ■ Reco

Change in Estimates

	Current FY26E	Previous FY27E	Current FY26E	Previous FY27E
Rating	BUY	BUY		
Target Price	1,730	1,730		
Sales (Rs. m)	2,98,949	3,20,499	2,99,572	3,21,578
% Chng.	(0.2)	(0.3)		
EBITDA (Rs. m)	71,983	75,308	73,954	74,253
% Chng.	(2.7)	1.4		
EPS (Rs.)	63.1	65.5	64.1	65.2
% Chng.	(1.5)	0.4		

Key Financials - Consolidated

Y/e Mar	FY24	FY25	FY26E	FY27E
Sales (Rs. m)	2,57,749	2,75,478	2,98,949	3,20,499
EBITDA (Rs. m)	62,919	71,281	71,983	75,308
Margin (%)	24.4	25.9	24.1	23.5
PAT (Rs. m)	41,224	52,727	50,962	52,896
EPS (Rs.)	51.1	65.3	63.1	65.5
Gr. (%)	47.1	27.9	(3.3)	3.8
DPS (Rs.)	12.9	15.9	16.9	19.9
Yield (%)	0.9	1.0	1.1	1.3
RoE (%)	16.5	18.2	15.5	14.5
RoCE (%)	20.4	20.4	18.1	17.1
EV/Sales (x)	4.7	4.4	4.0	3.7
EV/EBITDA (x)	19.5	17.2	16.7	15.6
PE (x)	29.8	23.3	24.1	23.2
P/BV (x)	4.6	3.9	3.5	3.2

Key Data

	CIPLA IN
52-W High / Low	Rs.1,702 / Rs.1,310
Sensex / Nifty	81,148 / 24,578
Market Cap	Rs.1,228bn / \$ 14,385m
Shares Outstanding	808m
3M Avg. Daily Value	Rs.2268.93m

Shareholding Pattern (%)

Promoter's	29.20
Foreign	26.28
Domestic Institution	27.89
Public & Others	16.63
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	3.9	1.0	7.5
Relative	(3.8)	(3.3)	(3.6)

Param Desai

paramdesai@plindia.com | 91-22-66322259

Kushal Shah

kushalshah@plindia.com | 91-22-66322490

In-line EBITDA; multiple niche launches to drive US sales

Quick Pointers:

- Guided for ~\$220mn US revs in Q1FY26.
- Margin guidance at 23.5%-24.5% in FY26.

CIPLA's Q4FY25 EBITDA (Rs15.4bn; 22.8% OPM) was in line with our estimates. While Q4 is seasonally weak quarter; margins at 23% were above our estimate. Despite delay in new launches and supply issues of gLanreotide; Cipla managed to deliver strong profitability/margins in H2FY25. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotinib, gAdvair. Further, Cipla's strong net cash position of +\$1bn provides flexibility to pursue strategic M&A opportunities. Our FY26E/27E EPS broadly remain unchanged. At CMP, stock is trading 23x FY26E EPS. We maintain our 'BUY' with TP of Rs1,730/share. Timely launch of critical high-value products in the US in FY26E/27E will be key.

- Domestic and One Africa portfolio supported revenue growth YoY:** CIPLA's Q4FY25 revenues were up 9% YoY to Rs67.3bn. Domestic formulation reported growth of 8% YoY, we est of 10% growth. Key therapies like Respiratory, Cardiac and Urology outpacing the market. US sales came in at \$221mn, down 2% QoQ (\$226mn in Q3). Lanreotide supplies normalise on QoQ basis. One Africa reported healthy growth of 20% YoY to Rs 10.2bn. API revenues declined 4% YoY.
- In line EBITDA, lower tax aided PAT:** GMs came in at 66.8%, up 50bps YoY but declined 70bps QoQ. CIPLA delivered EBITDA of Rs15.4bn, in line with our estimate. OPM stood at 22.8%, up 180bps YoY. R&D expenses stood at Rs4.3bn, 6% of revenue, down 4% YoY. Ex R&D cost other expenses were up 6% YoY. Other income came in higher at Rs 2.9bn whereas tax was lower at 19%. Resultant PAT stood at Rs12.3bn; sharply above our estimates. Reported EPS of Rs 15/share during the quarter.
- Key concall takeaways: Domestic formulation:** In Q4 FY25, the chronic portfolio mix held steady at 61.5%, with key chronic therapies—Respiratory, Cardiac, and Urology—continuing to outperform market growth. The trade generics segment maintained its strong upward momentum. Cipla remains focused on driving innovation, with upcoming launches including inhaled insulin and Plazomycin. **Consumer health:** The segment delivered robust double-digit growth both in the quarter and for the full FY25. Nicotex, Omnidex, and Cipladine continued to hold market leadership positions in their respective categories. **US business:** Cipla secured 3 key US drug approvals, including Nanopaclitaxel and Nilotinib; Nanopaclitaxel is launched in EM/EU, with a US launch soon. gAlbuterol held an 18% market share in Q4. **Upcoming launches:** gAdvair (FY26), Symbicort, QVAR. **Pipeline:** 6 respiratory assets filed, with 4 more expected in 12–18m. Filed 9 peptides/complex generics whereas 10 more planned, with 2–3 peptide launches in FY26. **One Africa:**

Cipla plans to launch the injectable Semaglutide in the first wave. The Actor acquisition boosted OTC growth, supported by a few tender wins. **Other highlights:** No tariff impact as US tariffs do not apply to Indian generics. R&D focus areas: Peptides, respiratory, biologics, and complex/long-acting injectables, expected to remain at 6–6.5% of revenue. ETR in FY25 was slightly lower due to reversal of earlier tax provisions and other adjustments. Capex to stay focused on de-risking facilities outside India. Debt: Rs 4.38 bn; Cash stands at Rs 108bn. **FY26 guidance:** Margin guidance at 23.5%-24.5% in FY26. Guided \$220mn US revs for Q1FY26 which factors in ramp up in Lanreotide recovery and QoQ decline in gRevlimid sales

Exhibit 1: 4QFY25 Result Overview (Rs mn) – In line EBITDA, Improved revenues YoY

Y/e March	4QFY25	4QFY24	YoY gr. (%)	3QFY25	QoQ gr. (%)	FY25	FY24	YoY gr. (%)
Net Sales	67,297	61,632	9.2	70,730	(4.9)	2,75,476	2,57,741	6.9
Raw Material	21,890	20,501	6.8	22,641	(3.3)	89,346	88,196	1.3
% of Net Sales	32.5	33.3		32.0		32.4	34.2	
Personnel Cost	12,331	10,842	13.7	11,976	3.0	48,328	43,100	12.1
% of Net Sales	18.3	17.6		16.9		17.5	16.7	
Others	17,700	17,130	3.3	16,224	9.1	66,579	63,534	4.8
% of Net Sales	26.3	27.8		22.9		24.2	24.7	
Total Expenditure	51,921	48,474	7.1	50,841	2.1	2,04,253	1,94,830	4.8
EBITDA	15,376	13,159	16.9	19,889	(22.7)	71,223	62,910	13.2
Margin (%)	22.8	21.4		28.1	(5.3)	25.9	24.4	
Depreciation	3,087	2,883	7.1	2,798	10.3	11,070	10,510	5.3
EBIT	12,289	10,275	19.6	17,091	(28.1)	60,153	52,400	14.8
Other Income	2,895	2,493	16.1	2,216	30.6	8,619	7,465	15.4
Interest	140	176	(20.3)	146	(4.2)	620	899	(31.0)
PBT	15,043	12,592	19.5	19,161	(21.5)	68,152	58,967	15.6
Extra-Ord. Inc./Exps.	-	-		-		-	(1,948)	
Total Taxes	2,793	3,249	(14.0)	3,324	(16.0)	15,298	15,466	(1.1)
ETR (%)	18.6	25.8		17.3		22.4	26.2	
Minority interest	(32)	46		(132)		(126)	(338)	
Reported PAT	12,218	9,390	30.1	15,705	(22.2)	52,729	41,215	27.9


Source: Company, PL

Exhibit 2: Sources of Revenue – Steady US revenues QoQ

Revenue break up (Rs mn)	4QFY25	4QFY24	YoY gr. (%)	3QFY25	QoQ gr. (%)	FY25	FY24	YoY gr. (%)
Domestic market	26,220	24,170	8.5	31,460	(16.7)	1,16,150	1,08,650	6.9
% of Sales	39.0	39.2		44.5		42.2	42.7	
International market (Exports)	41,070	37,470	9.6	39,270	4.6	1,59,330	1,45,890	9.2
% of Sales	61.0	60.8		55.5		57.8	57.3	
North America	19,190	18,750	2.3	19,060	0.7	78,990	75,000	5.3
% of Sales	28.5	30.4		26.9		28.7	29.5	
SAGA	10,190	8,470	20.3	9,750	4.5	38,270	33,440	14.4
% of Sales	15.1	13.7		13.8		13.9	13.1	
International markets	8,950	7,420	20.6	8,240	8.6	33,050	28,000	18.0
% of Sales	13.3	12.0		11.6		12.0	11.0	
APIs	1,820	1,890	(3.7)	1,260	44.4	5,660	5,810	(2.6)
% of Sales	2.7	3.1		1.8		2.1	2.3	
Others	920	940	(2.1)	960	(4.2)	3,360	3,640	(7.7)
% of Sales	1.4	1.5		1.4		1.2	1.4	
Total	67,290	61,640	9.2	70,730	(4.9)	2,75,480	2,54,540	8.2


Source: Company, PL

Exhibit 3: Maintained strong traction by trade generics




Source: Company, PL

Exhibit 4: Lanreotide supplies normalises QoQ




Source: Company, PL

Exhibit 5: *One Africa: Actor pharma + Tender wins aided performance




Source: Company, PL

Exhibit 6: Domestic formulation & International markets support growth



Source: Company, PL

Exhibit 7: GMs flat YoY, Ex R&D cost remained higher



Source: Company, PL

Financials

Income Statement (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
Net Revenues	2,57,749	2,75,478	2,98,949	3,20,499
YoY gr. (%)	13.3	6.9	8.5	7.2
Cost of Goods Sold	98,533	1,02,543	1,16,219	1,25,281
Gross Profit	1,59,216	1,72,934	1,82,730	1,95,217
Margin (%)	61.8	62.8	61.1	60.9
Employee Cost	38,752	44,110	49,004	53,905
Other Expenses	57,545	57,544	61,743	66,005
EBITDA	62,919	71,281	71,983	75,308
YoY gr. (%)	25.2	13.3	1.0	4.6
Margin (%)	24.4	25.9	24.1	23.5
Depreciation and Amortization	10,510	11,070	11,844	12,673
EBIT	52,409	60,211	60,138	62,634
Margin (%)	20.3	21.9	20.1	19.5
Net Interest	899	620	500	400
Other Income	7,466	8,619	9,500	10,500
Profit Before Tax	58,975	68,210	69,138	72,734
Margin (%)	22.9	24.8	23.1	22.7
Total Tax	15,466	15,298	17,976	19,638
Effective tax rate (%)	26.2	22.4	26.0	27.0
Profit after tax	43,510	52,912	51,162	53,096
Minority interest	-	-	-	-
Share Profit from Associate	(338)	(185)	(200)	(200)
Adjusted PAT	41,224	52,727	50,962	52,896
YoY gr. (%)	47.1	27.9	(3.3)	3.8
Margin (%)	16.0	19.1	17.0	16.5
Extra Ord. Income / (Exp)	1,948	-	-	-
Reported PAT	43,172	52,727	50,962	52,896
YoY gr. (%)	44.7	22.1	(3.3)	3.8
Margin (%)	16.7	19.1	17.0	16.5
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	43,172	52,727	50,962	52,896
Equity Shares O/s (m)	807	807	807	807
EPS (Rs)	51.1	65.3	63.1	65.5

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
Non-Current Assets				
Gross Block	1,59,099	1,72,602	1,87,602	2,02,602
Tangibles	1,08,114	1,17,290	1,27,483	1,37,676
Intangibles	50,985	55,312	60,119	64,926
Acc: Dep / Amortization	95,284	1,06,353	1,18,197	1,30,871
Tangibles	54,762	61,124	67,931	75,215
Intangibles	40,521	45,229	50,266	55,656
Net fixed assets	63,816	66,249	69,404	71,731
Tangibles	53,352	56,166	59,551	62,461
Intangibles	10,464	10,083	9,853	9,270
Capital Work In Progress	11,527	15,663	15,663	15,663
Goodwill	31,120	32,703	32,703	32,703
Non-Current Investments	55,628	80,440	80,440	80,440
Net Deferred tax assets	4,025	5,913	5,913	5,913
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	52,380	56,421	63,066	67,612
Trade receivables	47,707	55,064	55,695	59,709
Cash & Bank Balance	8,750	7,998	30,440	52,823
Other Current Assets	50,201	52,402	55,023	57,774
Total Assets	3,21,300	3,67,422	4,02,915	4,38,936
Equity				
Equity Share Capital	1,615	1,615	1,615	1,615
Other Equity	2,65,450	3,10,319	3,45,293	3,79,378
Total Networth	2,67,064	3,11,934	3,46,907	3,80,993
Non-Current Liabilities				
Long Term borrowings	2,254	2,524	2,524	2,524
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	3,340	1,857	357	17
Trade payables	24,740	28,375	30,304	32,489
Other current liabilities	26,968	27,686	27,776	27,867
Total Equity & Liabilities	3,21,300	3,67,422	4,02,915	4,38,936

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
PBT	58,975	68,210	69,138	72,734
Add. Depreciation	10,510	11,070	11,844	12,673
Add. Interest	899	620	500	400
Less Financial Other Income	7,466	8,619	9,500	10,500
Add. Other	(5,010)	(3,611)	(200)	(200)
Op. profit before WC changes	65,375	76,288	81,283	85,608
Net Changes-WC	(8,061)	(9,557)	(7,876)	(9,036)
Direct tax	(15,975)	(16,681)	(17,976)	(19,638)
Net cash from Op. activities	41,339	50,050	55,431	56,933
Capital expenditures	(16,160)	(15,234)	(15,000)	(15,000)
Interest / Dividend Income	-	-	-	-
Others	-	-	-	-
Net Cash from Inv. activities	(16,160)	(15,234)	(15,000)	(15,000)
Issue of share cap. / premium	-	-	-	-
Debt changes	(2,996)	(980)	(1,500)	(340)
Dividend paid	(6,862)	(10,498)	(15,989)	(18,810)
Interest paid	(899)	(620)	(500)	(400)
Others	(21,319)	(23,469)	-	-
Net cash from Fin. activities	(32,075)	(35,568)	(17,989)	(19,550)
Net change in cash	(6,897)	(751)	22,442	22,383
Free Cash Flow	28,187	34,816	40,431	41,933

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY24	FY25	FY26E	FY27E
Per Share(Rs)				
EPS	51.1	65.3	63.1	65.5
CEPS	64.1	79.0	77.8	81.2
BVPS	330.8	386.4	429.7	471.9
FCF	34.9	43.1	50.1	51.9
DPS	12.9	15.9	16.9	19.9
Return Ratio(%)				
RoCE	20.4	20.4	18.1	17.1
ROIC	16.8	16.8	16.1	16.2
RoE	16.5	18.2	15.5	14.5
Balance Sheet				
Net Debt : Equity (x)	0.0	0.0	(0.1)	(0.1)
Net Working Capital (Days)	107	110	108	108
Valuation(x)				
PER	29.8	23.3	24.1	23.2
P/B	4.6	3.9	3.5	3.2
P/CEPS	23.7	19.2	19.5	18.7
EV/EBITDA	19.5	17.2	16.7	15.6
EV/Sales	4.7	4.4	4.0	3.7
Dividend Yield (%)	0.9	1.0	1.1	1.3

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q1FY25	Q2FY25	Q3FY25	Q4FY25
Net Revenue	66,939	70,510	70,730	67,297
YoY gr. (%)	5.8	5.6	7.1	9.2
Raw Material Expenses	21,929	22,886	22,641	21,890
Gross Profit	45,011	47,624	48,089	45,407
Margin (%)	67.2	67.5	68.0	67.5
EBITDA	17,158	18,800	19,889	15,376
YoY gr. (%)	14.9	8.4	13.8	16.9
Margin (%)	25.6	26.7	28.1	22.8
Depreciation / Depletion	2,467	2,717	2,798	3,087
EBIT	14,691	16,082	17,091	12,289
Margin (%)	21.9	22.8	24.2	18.3
Net Interest	180	154	146	140
Other Income	1,602	1,906	2,216	2,895
Profit before Tax	16,114	17,835	19,161	15,043
Margin (%)	24.1	25.3	27.1	22.4
Total Tax	4,351	4,830	3,324	2,793
Effective tax rate (%)	27.0	27.1	17.3	18.6
Profit after Tax	11,763	13,004	15,837	12,250
Minority interest	(14)	(25)	132	32
Share Profit from Associates	-	-	-	-
Adjusted PAT	11,776	13,029	15,705	12,218
YoY gr. (%)	18.3	15.2	48.7	30.1
Margin (%)	17.6	18.5	22.2	18.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	11,776	13,029	15,705	12,218
YoY gr. (%)	18.3	15.2	48.7	30.1
Margin (%)	17.6	18.5	22.2	18.2
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	11,776	13,029	15,705	12,218
Avg. Shares O/s (m)	804	804	804	804
EPS (Rs)	14.6	16.2	19.5	15.2

Source: Company Data, PL Research

Key Operating Metrics

Y/e Mar	FY24	FY25	FY26E	FY27E
India Formulations	1,08,650	1,16,150	1,28,721	1,41,864
Exports	1,40,104	1,53,668	1,64,115	1,72,033
APIs	5,810	5,660	6,113	6,602

Source: Company Data, PL Research

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	11-Apr-25	BUY	1,730	1,416
2	08-Apr-25	BUY	1,730	1,385
3	29-Jan-25	BUY	1,730	1,421
4	08-Jan-25	BUY	1,730	1,497
5	28-Nov-24	BUY	1,730	1,493
6	30-Oct-24	Accumulate	1,615	1,478
7	07-Oct-24	Accumulate	1,680	1,623
8	28-Jul-24	Accumulate	1,680	1,575
9	08-Jul-24	Accumulate	1,405	1,510

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Apollo Hospitals Enterprise	BUY	8,100	6,683
2	Aster DM Healthcare	BUY	620	476
3	Aurobindo Pharma	BUY	1,510	1,097
4	Cipla	BUY	1,730	1,416
5	Divi's Laboratories	Accumulate	6,250	5,309
6	Dr. Reddy's Laboratories	Reduce	1,335	1,088
7	Eris Lifesciences	BUY	1,450	1,275
8	Fortis Healthcare	BUY	760	636
9	HealthCare Global Enterprises	BUY	555	523
10	Indoco Remedies	Hold	325	233
11	Ipca Laboratories	Accumulate	1,700	1,316
12	J.B. Chemicals & Pharmaceuticals	BUY	2,075	1,518
13	Jupiter Life Line Hospitals	BUY	1,750	1,480
14	Krishna Institute of Medical Sciences	BUY	725	567
15	Lupin	BUY	2,420	1,923
16	Max Healthcare Institute	BUY	1,300	1,084
17	Narayana Hrudayalaya	BUY	1,560	1,644
18	Rainbow Children's Medicare	BUY	1,785	1,406
19	Sun Pharmaceutical Industries	BUY	2,275	1,677
20	Sunteck Realty	BUY	650	401
21	Torrent Pharmaceuticals	Accumulate	3,750	3,234
22	Zydus Lifesciences	Accumulate	1,050	841

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

